Publicaţii

1. Diaconu I, Cerullo V, Escutenaire S, Kanerva A, Bauerschmitz GJ, Hernandez-Alcoceba R, Pesonen S and Hemminki A
Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir
J Gene Medicine. 2010

2. Cerullo V,Pesonen S, Diaconu I, Escutenaire S, Arstila P, Ugolini M, Nokisalmi P, Raki M, Laasonen L, Särkioja M, Rajecki M, Kangasniemi L, Guse K, Helminen A, Ahtiainen L, Ristimäki A, Räisänen-Sokolowski A, Haavisto E, Oksanen M, Karli E, Karioja-Kallio A, Holm S, Kouri M, Joensuu T, Kanerva A, Hemminki A.
Oncolytic adenovirus coding for GMCSF induces anti-tumoral immunity in human cancer patients.
Cancer Res. 2010

3. Dias JD, Liikanen I, Guse K, Foloppe J, Sloniecka M, Diaconu I, Eriksson M, Hakkarainen T, Lusky M, Erbs P, Escutenaire S, Kanerva A, Pesonen S, Cerullo V, Hemminki A
Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1, a fusion of cytosine deaminase and uracil phosphoribosyltransferase
Clin Cancer Res. 2010

4. Dias JD, Guse K, Nokisalmi P, Eriksson M, Chen DT, Diaconu I, Tenhunen M, Liikanen I, Grenman R, Savontaus M, Pesonen S, Cerullo V, Hemminki A.
Multi-modal approach using oncolytic adenovirus, cetuximab, chemotherapy, and radiation in HNSCC clinial tumor explants.
Eur J Cancer.2010 Feb;46(3):625-35

5. Guse K, Sloniecka M, Diaconu I, Le Boeuf F, Bell JC, McCart JA, Pesonen S, Cerullo V, Hemminki A.
Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.
J Virol. 2010 Jan;84(2):856-66.

6. Budiu RA, Diaconu I, Chrissluis R, Dricu A, Edwards RP, Vlad AM
Conditional mouse model for human MUC1-positive endometriosis shows presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells
Dis Model Mech.2009 Nov-Dec;2 (11-12):593-603.

7. Guse K, Diaconu I, Rajecki M, Sloniecka M, Hakkarainen T, Ristimäki A, Kanerva A, Pesonen S, Hemminki A.
Ad5/3-9HIF-Δ24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic, oncolytic adenovirus for treatment of renal cell cancer.
Gene Ther. 2009 Aug; 16(8):1009-20. Epub 2009 May 14.

8. Diaconu I, Denby L, Pesonen S, Bauerschmitz GJ, Guse K, Rajecki M, Dias JD, Taari K , Kanerva A, Baker AH, Hemminki A.
Serotype chimeric and fiber mutated adenovirus Ad5/19p-HIT for targeting renal cancer and untargeting the liver.
Hum Gene Ther. 2009 Jun;20(6):611-20

9. L Kangasniemi, M Koskinen, M Jokinen, M Toriseva, R Ala-Aho, V-M Kähäri, H Jalonen, S Ylä-Herttuala, H Moilanen, U-H Stenman, I Diaconu, A Kanerva, S Pesonen, T Hakkarainen & A Hemminki,
Extended release of adenovirus from silica implants in vitro and in vivo
Gene Therapy, 2009 Jan;16(1):103-10. Epub 2008 Aug 28.

10. Anda M. Vlad, Iulia Diaconu and Kira R. Gantt,
MUC1 in endometriosis and ovarian cancer
Immunologic Research, 2006;36(1-3):229-36.